Solid forms of rxfp1 modulators
AssigneesAstraZeneca AB, Mitsubishi Tanabe Pharma Corporation
InventorsInge Torbjörn ARVIDSSON, Marika Jenny Susanna LINDHAGEN, Okky Dwichandra PUTRA, Hosam Al-Deen ABU AWWAD, Philip Anthony CORNER, Dhaval Rasikbhai KALARIA
Life of this patent
Estimating the term…
Abstract
The specification generally relates to solid forms, for example, crystalline and amorphous forms, of (1S,4s)-4-(2-fluoro-4-methoxy-5-(((1S,2R,3S,4R)-3-(((1-methylcyclobutyl)methyl)carbamoyl)bicyclo[2.2.1]heptan-2-yl)carbamoyl)phenoxy)-1-methylcyclohexane-1-carboxylic acid (Compound (I)). In particular, an amorphous form of Compound (I), solid dispersions and pharmaceutical compositions comprising such an amorphous form, and crystalline Form G of Compound (I).
Claims24
Amorphous Compound (I)
A pharmaceutical composition comprising amorphous Compound (I) and a pharmaceutically acceptable excipient.
A solid dispersion comprising amorphous Compound (I).
The compound, solid dispersion or pharmaceutical composition of any one of the preceding claims for use in therapy.
A crystalline form of Compound (I), wherein the crystalline form has a melting onset at about 217.5° C.
A crystalline form of Compound (I), obtainable by heating crystalline Form A of Compound (I) to a temperature above about 43.9° C., optionally above about 45° C. optionally above about 50° C., optionally above about 55° C., optionally above about 60° C., optionally above about 65° C.
Dependencies are inferred from the claim text.